MICA: Pulmonary Hypertension: intensification and personalisation of combination Rx (PHoenix)
MICA:肺动脉高压:联合 Rx 的强化和个性化 (PHoenix)
基本信息
- 批准号:MR/W026279/1
- 负责人:
- 金额:$ 173.33万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2023
- 资助国家:英国
- 起止时间:2023 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Pulmonary arterial hypertension (PAH) is a devastating disease driven by remodelling and constriction of the small blood vessels of the lungs. Approved therapies reduce constriction by targeting three distinct biological pathways. Therapies are changed due to side effects and/or disease worsening. However, due to the invasive, hospital-based investigations required to assess disease severity and demonstrate benefit of treatment, there is no way to match patients to drugs effective for their disease. Through an MRC Confidence-in-Concepts funded feasibility study we have developed the capacity to use regulatory approved, minimally-invasive monitors to make key measurements that allow assessment of disease severity and treatment effect while patients are at home. Data is relayed daily to care teams through regulatory approved, clinically used online portals, making early, remote evaluation of treatment benefit in an individual patient possible. In patients with pulmonary arterial hypertension (PAH) this study will: evaluate the capacity of implantable/remote technology for early evaluation of clinical efficacy and matching patients to drugs that work for them.Forty patients with PAH established on guideline recommended therapy will be implanted with approved medical devices and remote monitoring established. Physiology, activity and quality-of-life will be monitored during a randomised cross-over study of oral prostacyclin IP receptor agonist and soluble guanylate cyclase stimulator. The study will assess the physiology of therapeutic intensification and de-escalation in a manner previously unachievable. If successful, the technological approach will facilitate novel study designs in the area, providing a platform that has the potential to transform experimental medicine, therapeutic development and personalised medicine for patients with pulmonary hypertension.
肺动脉高压(PAH)是一种由肺小血管重构和收缩引起的破坏性疾病。批准的治疗方法通过靶向三种不同的生物途径来减少收缩。治疗方法会因副作用和/或疾病恶化而改变。然而,由于需要进行侵入性的、以医院为基础的调查,以评估疾病的严重性并证明治疗的好处,因此无法将患者与有效治疗其疾病的药物相匹配。通过MRC对概念的信心资助的可行性研究,我们开发了使用监管批准的微创监测器进行关键测量的能力,以便在患者在家时评估疾病严重程度和治疗效果。数据每天通过监管部门批准的临床使用的在线门户网站传递给护理团队,使早期、远程评估个别患者的治疗益处成为可能。在肺动脉高压(PAH)患者中,这项研究将评估植入性/远程技术早期评估临床疗效的能力,并将患者与对他们有效的药物配对。40名根据指南推荐治疗建立的PAH患者将被植入经批准的医疗设备并建立远程监测。在口服前列环素IP受体激动剂和可溶性鸟苷环化酶刺激剂的随机交叉研究中,将监测生理、活动和生活质量。这项研究将以一种以前无法实现的方式评估治疗强化和降级的生理学。如果成功,该技术方法将促进该领域的新研究设计,提供一个有潜力改变实验医学、治疗开发和为肺动脉高压患者提供个性化药物的平台。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Remote evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension
肺动脉高压患者治疗升级和临床恶化的风险和生理反应的远程评估
- DOI:10.1101/2023.04.27.23289153
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Middleton J
- 通讯作者:Middleton J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Rothman其他文献
Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study
- DOI:
10.1186/s12890-024-03442-7 - 发表时间:
2024-12-18 - 期刊:
- 影响因子:2.800
- 作者:
Rachael Kendrew;Salma Ajraoui;Amélie Beaudet;Kimberly Kelly;David G Kiely;Alexander Rothman;Frances Varian;Stacy Davis;Nadia Pillai - 通讯作者:
Nadia Pillai
Alexander Rothman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Rothman', 18)}}的其他基金
Investigation of MiR-140-5p in Humans and Experimental Models of Pulmonary Arterial Hypertension.
MiR-140-5p 在人类和肺动脉高压实验模型中的研究。
- 批准号:
MR/K002406/1 - 财政年份:2012
- 资助金额:
$ 173.33万 - 项目类别:
Fellowship
相似海外基金
PHORA-Pulmonary Hypertension Outcome Risk Assessment
PHORA-肺动脉高压结果风险评估
- 批准号:
10990081 - 财政年份:2024
- 资助金额:
$ 173.33万 - 项目类别:
THE ROLE OF EXERCISE DURING HEMODYNAMIC ASSESSMENT TO IMPROVE PULMONARY HYPERTENSION DIAGNOSIS IN OLDER ADULTS
运动在血流动力学评估过程中对改善老年人肺动脉高压诊断的作用
- 批准号:
495417 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Elucidation of distinct regulatory mechanisms of NCX1/NCX2 in pulmonary arterial hypertension
阐明 NCX1/NCX2 在肺动脉高压中的不同调节机制
- 批准号:
23K06374 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Standard Grant
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244996 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Standard Grant
REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension
REVAMP-PH:重新利用缬沙坦可以预防肺动脉高压
- 批准号:
10642368 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Proteomic Signatures Associated with Right Ventricular Failure and Mortality in Pulmonary Arterial Hypertension
与肺动脉高压右心室衰竭和死亡率相关的蛋白质组学特征
- 批准号:
10675409 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Pulmonary Hypertension: State of the Art and Therapeutic Opportunities
肺动脉高压:最新技术和治疗机会
- 批准号:
10682118 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
Metabolic mechanisms underlying bronchopulmonary dysplasia-associated pulmonary hypertension
支气管肺发育不良相关肺动脉高压的代谢机制
- 批准号:
10736803 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别:
General Capillary to Arterial Endothelial Cell Transition in Pulmonary Arterial Hypertension
肺动脉高压中毛细血管内皮细胞向动脉内皮细胞的转变
- 批准号:
10716738 - 财政年份:2023
- 资助金额:
$ 173.33万 - 项目类别: